Minimal phenotyping refers to the reliance on self-reported responses to one or two questions for disease case identification. This strategy has been applied to genome-wide association studies (GWAS) of major depressive disorder (MDD). Here we report that the genotype derived heritability (h 2 SNP) of depression defined by minimal phenotyping (14%, SE = 0.8%) is lower than strictly defined MDD (26%, SE = 2.2%), and that it shares as much genetic liability with strictly defined MDD (0.81, SE = 0.03) as it does with neuroticism (0.84, SE = 0.05), a trait not defined by the cardinal symptoms of depression. While they both show similar shared genetic liability with the personality trait neuroticism, a greater proportion of the genome contribute to the minimal phenotyping definitions of depression (80.2%, SE = 0.6%) than to strictly defined MDD (65.8%, SE = 0.6%). We find that GWAS loci identified in minimal phenotyping definitions of depression are not specific to MDD: they also predispose to other psychiatric conditions. Finally, genetic predictors based on minimal phenotyping definitions are not predictive of strictly defined MDD in independent cohorts. Our results reveal that genetic analysis of minimal phenotyping definitions of depression identifies non-specific genetic factors shared between MDD and other psychiatric conditions. Reliance on results from minimal phenotyping for MDD may thus bias views of the genetic architecture of MDD and impedes ability to identify pathways specific to MDD.
Introduction
There is now little doubt that a key requisite for the robust identification of genetic risk loci underlying psychiatric disease is the use of an appropriately large sample. However, while the costs of genotyping and sequencing continue to fall, the cost of phenotyping remains high 1 , limiting sample collection. One solution for reducing the burden of case identification is to utilize minimal phenotyping, such as clinical information from hospital registers 2 , or reliance on subjects' self-reported symptoms, help-seeking, diagnoses or medication, which are cheap and fast to collect. We refer to the latter strategy as "minimal phenotyping", as it minimizes phenotyping costs and reduces data to a single or few self-reported answers.
However, apart from the detection of more and more GWAS loci [3] [4] [5] (Supplemental Table S1 ), the consequences of sacrificing symptomatic information for genetic analyses has rarely been investigated. The consequences may be particularly important for major depressive disorder (MDD) because of its phenotypic and likely etiological heterogeneity 6 , high degree of comorbidity with other psychiatric diseases 7 , and substantial discrepancies between self-assessment using symptom scales and diagnoses made with full diagnostic criteria 8 . While a majority of the population self-identify as having one or two depressive symptoms at any one time, only between 9 and 20% of the population have sufficient symptoms to meet criteria for lifetime occurrence of MDD [8] [9] [10] . Similarly, self-report of diagnosis or prescribed treatment, as employed by 23andMe, can be affected by the low rate of help-seeking among those who meet MDD diagnostic criteria (~50%) [11] [12] [13] , false positives equalling true positives in primary care diagnoses unassisted with diagnostic criteria (by ~50%) 12 , and high rates of anti-depressant prescription for a wide range of conditions [13] [14] [15] . As such, a cohort of MDD cases obtained through the use of self-report of either illness or prescribed treatment may yield a sample that is not representative of the clinical disorder, but enriched in those with non-specific sub-clinical depressive symptoms and depression secondary to a comorbid disease.
By comparing the genetic architecture of minimal phenotyping definitions of depression with those using full diagnostic criteria for MDD in UKBiobank 16 , a community-based survey of half a million men and women, we assess the implications of a minimal phenotyping strategy for GWAS in MDD. We find that MDD defined by minimal phenotyping has a large non-specific component, and if GWAS loci from these definitions are chosen for follow-up molecular characterization, they may not be informative about biology specific to MDD.
Results

Definitions of depression in UKBiobank
The diverse assessments of depression in the UK Biobank provide an opportunity to determine the impact that differences in diagnostic criteria have on findings of depression's genetic architecture. We identified five ways that MDD can be defined in UKBiobank. First, using self-reports of seeking medical attention for depression or related conditions, we identified "Help-seeking" definitions of MDD (referred to as "broad depression" in a previous GWAS 3 ). Second, participants were diagnosed with "Symptom-based" MDD if, in addition to meeting the help seeking criteria described above, they reported ever experiencing one or more of the two cardinal features of depression (low mood or anhedonia) for at least two weeks (this is the "probable MDD" diagnosis available in UKBiobank 17 ). Third, we define a "Self-Report" form of depression based on participants' self-reports of all past and current medical conditions to trained nurses. Fourth, information from electronic health records can be used to assign an ICD10 primary and secondary illness codes from the label as "EMR". Finally, a "DSM-based" diagnosis of lifetime MDD was derived from subjects who answered an online "Mental Health Follow-up" questionnaire (MHQ) 18 which included DSM-5 criteria for MDD (Supplemental Methods, Supplemental Figure S1 , Supplemental Table S2 ). None of the definitions uses trained interviewers applying structured clinical interviews, and only the last applies operationalized criteria including symptoms, length of episode (more than two weeks) and impaired social, occupational or educational function. From hereon we refer to definitions one to three as 'minimal', the fourth as "EMR-based", and the fifth as 'strictly' defined MDD (Supplemental Methods).
We also included a category of participants who met the Help-seeking based definition (part of "broad depression" in Howard et al 2018 3 ) but failed to meet the symptom based definition (as they had neither of the two cardinal symptoms of depression: depressed mood or a loss of interest or pleasure in daily activities for more than two weeks). This group we refer to as "Non-MDD" (described in detail in Supplemental Methods, Supplemental Table S3 ). They provide a control for the specificity of genetic effects on depression. Figure 1 outlines the different diagnostic categories and the numbers of samples that each contains.
There are several features to these definitions of MDD we recognize as important for the comparison of their genetic architecture. First, for each diagnostic category we used controls who were asked the relevant questions but failed to meet criteria. As such, cases from one category can be controls in another, resulting in substantial overlap in both cases and controls between categories (Supplemental Figure S2 ), which impacts assessment of genetic architecture and genetic correlation between them 19 . Second, not all participants in UKBiobank were asked questions from all categories. For example, questions for the Symptom-based definition DepAll were asked in only 10 out of 22 assessment centers in UKBiobank ( Supplemental Table S4 ), and the MHQ was only answered in full by 31% of the original UK Biobank participants, resulting in differences in population structure between definitions that need to be considered in analysis (Supplemental Methods, Supplemental Figure S3 ).
Third, different definitions of depression have different prevalence in the UKBiobank cohort (from 0.078 to 0.341, Supplemental Table S5 ). Though unlikely biased due to population structure ( Supplemental   Tables S6-7) , the wide range of prevalence may be due to self-ascertainment biases. In general, the UKBiobank is known for higher participation rates from women who are older, more well-off, and better educated 20 . One example of self-ascertainment of particular interest to our analysis is the voluntary participation in the MHQ, which has been shown to have a genetic component that can be genetically correlated with that of mental health conditions 21 . All such biases can have confounding effects on genetic studies of depression phenotypes derived from it. We verified that, though ascertainment biases exist, they cannot account for the results we present in this paper (Supplemental Methods, Supplemental Figure 4 , Supplemental Table S8-9) .
Finally, many previous GWAS on depression (and any other disease) apply other filters in the selection of cases and controls, in addition to case criteria. One such example is the use of "clean controls" which requires individuals who are designated as "controls" do not endorse any of the case criteria. We do not use "clean controls" in this study, as that violates key assumptions in our analyses of genetic architecture (Supplemental Methods), although we show this strategy can increase power in GWAS as compared to using all controls (Supplemental Tables S10-11, Supplemental Figure S5 ).
Minimal phenotyping definitions of depression are epidemiologically different from strictly defined
MDD
We began our examination of the different definitions of MDD by looking at how known risk factors for depression impacted on each. We assessed whether risk factors were similar between definitions of depression 22 . Figure 2a -g shows the mean effect (odds ratio, OR) with confidence intervals of each of the following risk factors: sex 23, 24 , age 25 , educational attainment [26] [27] [28] , socio-economic status 29 , neuroticism 30, 31 , experience of stressful life events in the two years leading up to the baseline assessment, and cumulative traumatic life events preceding assessment 32, 33 (Supplemental Methods, Supplemental Table S12 ).
Estimates of the risk factor effect sizes differed substantially, and often highly significantly, as shown by the confidence intervals in Figure 2 . We asked if differences in risk factors can be used to classify definitions of depression. We applied a clustering algorithm and found that all minimal phenotyping definitions of depression cluster separately from strictly defined MDD ( Figure 2h ).
Minimal definitions of depression are not just milder or noisier version of strictly defined MDD
We next addressed the question of the genetic relationship between the different MDD definitions. We found that depression defined by minimal phenotyping strategies have lower SNP-based heritabilities (h 2 SNP) than more strictly defined definitions ( Figure 3a ). Self-report (SelfRepDep h 2 SNP = 11%, se = 0.85%) and help-seeking based definitions (Psypsy h 2 SNP = 13%, se = 1.18%; GPpsy h 2 SNP = 14%, se = 0.81%) have heritabilities of 15% or less. By contrast, strictly defined MDD (LifetimeMDD) has a much higher h 2 SNP of 26% (se = 2.15%); imposing the further criterion of recurrence brings the h 2 SNP up to 32% (se = 2.56%). Other definitions have intermediate h 2
SNP.
All h 2 SNP estimates were estimated on the liability scale using PCGCs 34 , a method specifically suited for analyses of case-control data with ascertainment bias, where covariates (especially those strongly correlated with the disease, induced by ascertainment biases) are appropriately handled 19 (Supplemental Methods).
We ensured that the trend we observe holds regardless of the method used 19, [35] [36] [37] (Supplemental Methods, Supplemental Table S13 ), and was not affected by regions of high linkage-disequilibrium or complexity 38 (Supplemental Methods, Supplemental Figure S3 ). For comparison, we provide h 2 SNP estimates from previous studies of MDD 4, 39, 40 (Supplemental Figure S6 ) and find that they fit squarely into the trend we observe: the less strict the criteria used to diagnose MDD, the lower the h 2
We explored the impact of case prevalence on estimates of h 2 SNP, since self-ascertainment biases prevalence rates derived from UK Biobank data. We used case prevalence corrected for age, sex and regional participation in UKBiobank 41 (Supplemental Methods, Supplemental Tables S5), as well as a constant case prevalence of 0.15, as used in previous studies on depression 5, 40 . Neither alters our results (Supplemental Figure S3 , Supplemental Tables S13). There is no realistic combination of prevalence across the definitions that would allow all of them to have the same h 2 SNP and to be consistent with previous reports on MDD 39,40 (Supplemental Figure S7 , See Supplemental Table S1 for all prevalence used in previous GWAS).
We examined the role of a number of additional factors for the lower h 2 SNP of minimal phenotyping definitions of MDD. First, we established that minimal phenotyping definitions do not simply have a higher environmental contribution to MDD than the stricter definitions. When we assessed h 2 SNP in MDD cases with high and low exposure to environmental risk factors 36, 42 we found that minimal phenotyping definitions of depression (GPpsy, SelfRepDep) show no significant difference between exposures, similar to or lower than strictly defined MDD (LifetimeMDD and MDDRecur) (Supplemental Methods, Supplemental Table S14 ).
Second, the minimal phenotyping definitions do not merely include milder cases of MDD as previously hypothesized 43 . Inclusion of milder cases is equivalent to lowering the threshold for disease liability in the population above which "cases" for MDD are defined. Under the liability threshold model 44 Figure S8 ). Instead, we show, through simulations, that the lower 
Genetic correlations between definitions of depression and other diseases
We found that the genetic correlation (rG) between minimal and strictly defined MDD includes a large proportion of non-specific liability to mental ill-health. The rG between GPpsy (minimal defined MDD) and LifetimeMDD (strictly defined MDD) is 0.81 (se = 0.03), significantly different than unity ( Figure 3b ).
One interpretation of this finding is that the correlation represents shared genetic liability to MDD 4,5 .
However, the majority of the genetic liability of LifetimeMDD due to GPpsy (approximately 0.81 2 =66%), is shared with the No-MDD definition, GPNoDep (that excluded MDD symptoms). The genetic liability of GPNoDep explains approximately 70% of the genetic liability of GPpsy (genetic correlation = 0.84, se = 0.05), and 34% of that of LifetimeMDD (genetic correlation = 0.58, se = 0.08). We next examined rG between different definitions of MDD and comorbid diseases. We used cross-trait LDSC 35 to estimate rG with neuroticism and smoking (Supplemental Figure S10 , Supplemental Tables   S15-16) in UKBiobank, as well as with all psychiatric conditions in the Psychiatric Genomics Consortium (PGC) 45 including PGC1-MDD 40 and depression defined in 23andMe 4 ( Supplemental Table S1 ). Figure 4a and Supplemental Table S17 shows few differences in rG estimates between other psychiatric disorders and the different definitions of MDD in UKBiobank, consistent with previous reports 46 .
However, similar rG estimates can result from different genetic architectures, indexed by the extent to which genetic liability is spread across the genome: it is spread more widely in a highly polygenic trait than a less polygenic trait. We estimated local rGL and percentage contribution to total rGT using rho-HESS 47 (Methods, Figure 4b ). 65.8% (SE = 0.6%), 37.1% (SE = 4.5%) and 42.7% (SE = 2.3%) of the genome explains 90% of the rGT between strictly defined MDD (LifetimeMDD) and neuroticism, BIP and SCZ respectively. In comparison, 80.2% (SE = 0.6%), 47.3% (SE = 2.4%) and 46.8% (SE = 0.2%) of the genome is needed to explain the same percentage of rGT between help-seeking based GPpsy and the same conditions ( Figure 4c ). In other words, minimal phenotyping definitions of depression share more genetic loci with other psychiatric conditions than strictly defined MDD.
Previous work 4 reported that depression defined through minimal phenotyping shows enrichment of h 2 SNP in regions of the genome encoding genes specifically and highly expressed in central nervous system (CNS) tissues represented in GTEx 48 . We assessed this in the definitions of depression in UKBiobank using LDSC-SEG 49 . As shown in Figure 5 , neither strictly defined MDD (LifetimeMDD) nor MDD defined based on structured clinical assessments in PGC1 show significant CNS enrichments. This is inconsistent with CNS enrichment in a larger PGC MDD cohort PGC29 5,50 (Methods, Supplemental Table S1, Supplemental Figure S11 ), and a previously reported meta-analysis between PGC29 and cohorts collected in other strategies 5 , including a dominant contribution from the minimal phenotyping defined depression in 23andMe 4 . As the latter is a heterogenous cohort collected with both structured interviews and electronic health records with varying degree of adherence to DSM criteria 50 (Supplemental Figure S14 , Supplemental   Table S20 ), this discrepancy reflects factors influencing results from enrichment analyses, including statistical power, diagnoses strategy, strictness of DSM diagnostic criteria. We provide a full discussion in Supplemental Methods. Also shown in Figure 5 , minimal phenotyping definition GPpsy showed a significant CNS enrichment (also see Supplemental Methods, Supplemental Figure S11 ). Notably, the non-MDD help-seeking definition GPNoDep also showed enrichment of h 2 SNP in genes specifically expressed in CNS, as did neuroticism, smoking, and other disorders in the PGC 45 such as schizophrenia 51 (SCZ) and bipolar disorder 52 (BIP). CNS enrichment therefore indexes genetic effects for many conditions rather than specifically MDD, and cannot alone be used to validate minimal phenotyping definitions of depression as being biologically relevant or equivalent to strictly-defined MDD.
GWAS hits from minimal phenotyping are not specific to MDD
We next examined the specificity of action of individual genetic loci found in GWAS of each definition of MDD. We found that the help-seeking definitions gave the greatest number of genome-wide significant hits (27 from GPpsy and Psypsy, Supplemental Table S10 ) in GWAS, consistent with their larger sample sizes and statistical power for finding associations. Are these loci relevant and specific to MDD, or are they nonspecific and shared with other conditions such as SCZ, neuroticism and smoking?
Of the 27 loci from minimal phenotyping definitions, 20 showed significant effects (at P<0·05 after multiple testing correction for 27 loci) on strictly defined LifetimeMDD despite its much smaller sample size. This is consistent with the hypothesis that using minimal phenotyping for GWAS of MDD can be useful for identifying loci relevant to MDD. However, all 20 loci also showed significant effects in neuroticism, smoking, SCZ, or the no-MDD help-seeking condition (GPNoDep, Supplemental Table S18 ), of which 10 show significant effects in GPNoDep. Note, that the sample size of GPNoDep (N = 58,125, case prevalence = 0.15) is similar (slightly lower) to that of LifetimeMDD (N = 67,171, case prevalence = 0.24), and as such high replication rates from GPNoDep cannot be attributed to higher power. Further, five loci showed significant replication only in neuroticism, and Figure 6 shows that the effects of all 27 loci on neuroticism mirror their effects on GPpsy. Hence, many of the loci relevant for MDD found using GWAS on minimal phenotyping definitions are not specific to MDD.
We find the same pattern of results when we use loci identified from a minimal phenotyping strategy in an independent study. The consumer genetics company 23andMe mapped loci that contribute to the risk of MDD defined by self-reports of receiving a doctor's diagnosis and treatment of depression 4 . Of the 17 loci, ten replicated in GPpsy (at P<0·05, after multiple testing correction for 17 loci), only 3 replicated in LifetimeMDD, all of which showed significant effects in neuroticism, smoking or SCZ (Supplemental Figure S12 , Supplemental Table S19 ) and are therefore not specific to MDD. None has a significant effect on LifetimeMDD alone. These results are consistent with what we observe of minimal phenotyping definitions in UKBiobank, and show that they primarily enables the discovery of pathways associated with depression that are shared with other conditions.
Out-of-sample prediction of MDD
Finally, we explored whether the definitions of depression in UKBiobank are genetically different by testing the extent to which they predict strictly defined, DSM-based MDD in independent cohorts. We carried out an out-of-sample prediction analysis using data from the MDD Working Group of the Psychiatric Genomics Consortium (PGC). We used 23 MDD cohorts from PGC29 5,50 , 20 of which recorded endorsement of DSM criteria A for MDD from structured interviews ( Supplemental Table S20 ). We constructed polygenic risk scores (PRS) on each definition of depression in UKBiobank (Methods) and examined their prediction in the PGC cohorts.
To ensure our results are not confounded by power differences due to differences in sample sizes between definitions of depression, we down-sampled all definitions to a constant sample size of 50,000 and case prevalence of 0.15, and obtained PRS using GWAS on the down-sampled data (Methods). As shown in Figure 7a , PRS from the strictly defined DSM-based MDD (LifetimeMDD) is the best predictor of MDD disease status in the 20 strictly defined PGC-MDD cohorts (Supplemental Figure S13 and Supplemental   Table S21 ). In contrast, PRS from minimal phenotyping, help-seeking based GPpsy show much lower prediction accuracy; PRS from the non-MDD definition GPNoDep has the lowest prediction accuracy.
We were able to explore the specificity of prediction by taking advantage of the fact that a proportion of cases in the PGC cohorts do not fulfill DSM-5 criteria MDD (Supplemental Methods, Supplemental Table   S20 , Supplemental Figure S14 ). We investigated the relationship between the prediction accuracy of PRS derived from each definition of depression in UKBiobank and the percentage of cases in each PGC cohort that fulfill DSM-5 criteria for MDD. Figure 7b shows that the Nagelkerke's r 2 values between PRS computed for LifetimeMDD and disease status in PGC-MDD cohorts are positively correlated with percentage of cases in each cohort that fulfill DSM-5 criteria A for MDD across all P value thresholds (maximum Pearson r between Nagelkerke's r 2 and percentage DSM-MDD cases in PGC cohorts = 0.46, P = 0.04 at PRS P value threshold = 0.05, Supplemental Table S22 ). There is no such trend for GPpsy (maximum Pearson r = 0.16, P = 0.50 at PRS P value threshold = 0.05, Supplemental Table S22 ). While larger sample sizes afforded by minimal phenotyping can increase predictive power, such that the minimal phenotyping definition GPpsy with the highest sample size outperforms all other definitions, prediction is not specific to MDD (Supplemental Methods, Supplemental Figure S15 , Supplemental Table S21 -22) .
Discussion
Though it is believed that the gain in statistical power from using larger sample sizes compensates for inaccuracies in minimal phenotyping 4, 5, 53, 54 , our study demonstrates that this approach yields loci that are more likely to be non-specific to MDD. Using a range of definitions of MDD in UKBiobank, from self-reported help-seeking to a full assessment of the DSM-5 criteria for MDD through self-reported symptoms from the MHQ, we made four observations. First, the heritabilities of depression defined by minimal phenotyping strategies are lower than MDD defined by full DSM-5 criteria. Second, although there is substantial genetic correlation between definitions, there remain significant differences, indicating the presence of genetic effects unique to each definition. Of the genetic liability shared between depression defined by minimal phenotyping and DSMbased MDD, a large proportion is not specific to MDD, as indexed by sharing with a non-MDD definition that excludes core depressive symptoms. Third, a larger proportion of genetic loci contributing to minimal phenotyping definitions of depression are shared with other psychiatric conditions than those contributing to DSM-based MDD, likely driving its enrichment of h 2 SNP in CNS-specific genes and shared effects at GWAS loci with other psychiatric conditions. Finally, PRS from minimal phenotyping definitions of depression perform poorly in predicting MDD status in independent cohorts, compared to PRS from strictly defined, DSM-based MDD. These results point to the non-specific nature of genetic factors identified in minimal phenotyping definitions of depression.
None of the definitions of depression in the UKBiobank were obtained from structured clinical interviews with an experienced rater (the gold standard for diagnosing MDD). The closest to that standard in UKBiobank is the online MHQ 18 , based on the Composite International Diagnostic Interview Short Form (CIDI-SF) 55 , but it should be pointed out that agreement between self-report measures and clinician ratings in other studies is typically low 56 (kappa coefficients of around 0.6 57 ). There is indeed evidence that selfreported diagnoses often over-estimate the prevalence of MDD based on interviews (for example in one population survey self-report questionnaire gave an estimate of 22.6 percent, compared to 8% based on interviews 58 ). Our results suggest that self-reported diagnoses using a CIDI-SF or other diagnostic questionnaires with full DSM criteria represent sub-clinical depression, lying on the same genetic liability continuum as MDD 43 . This would argue that collecting MDD cases through self-report means, using a full diagnostic questionnaire is potentially justified. The cases will be enriched for more strictly defined forms, with the consequence that results from genetic analysis will include loci that contribute to strictly defined MDD disease risk 59, 60 .
In contrast, we show that minimal definitions of MDD do not simply include cases with lower genetic liability to MDD, and that PRS derived from minimal definitions are poor predictors of strictly defined MDD in independent samples. While it is true there is a high degree of genetic correlation between MDD and depressive symptoms (0.7, implying roughly 49% of genetic liability to both conditions are shared) 22 , it is also true that there is an even higher degree of sharing between depressive symptoms and other traits such as neuroticism (0.79-0.94, implying roughly 62%-88% sharing of genetic liability, especially if both were assayed at a single time point 61 ). In other words, the correlation is driven by non-specific genetic risk factors. This is consistent with a recent study of three large twin cohorts, which asked if a combination of MDD, depressive symptoms and neuroticism is able to capture all genetic liability of MDD 62 . This study showed that 65% of the genetic effects contributing to MDD are specific, and minimally defined depression (inclusive of MDD, depressive symptoms and neuroticism) can index only around one-third of the genetic liability to MDD. The broad impact of the shared genetic liability, increasing predisposition to a number of psychiatric illnesses, reveals that it indexes a liability to poor mental health in general, rather than to MDD in particular.
As expected from our analysis of heritabilities, genetic correlations and PRS, genetic loci found for minimal definitions of MDD are not specific to MDD. This has important implications for downstream investigations. The biological information from a minimal definition of MDD in terms of genes and pathways discovered may be informative about mental ill health in general, but not MDD in particular. One interpretation is that the characterization of genetic loci with such non-specific effects will still advance understanding of the biology of psychiatric disorders and their treatment 5, 53 . A recent report on genetic analyses of subjective well-being, depressive symptoms and neuroticism identified a high degree of sharing between genetic liabilities to the three measures, and use the "quasi-replication" of GWAS loci between depressive symptoms and neuroticism as validation of their functional significance 63 . An alternative view is that these loci reflect the ways in which depressive symptoms can develop as secondary effects, including through susceptibility to adverse life events 64 , personality types 30 , and use or exposure to psychoactive agents like cigarette smoking 65, 66 . In which case, while useful for understanding the basis of mental ill health, they are not informative about the genetic etiology of MDD.
The lack of CNS h 2 SNP enrichment in strictly-defined MDD, although present in published studies and minimal phenotyping definitions of depression, may seem counterintuitive. Many factors influence the results of this analysis including statistical power. Nevertheless, the non-specificity of CNS enrichment to MDD precludes its use for validation of any definition of depression. Our assumptions of a CNS involvement in MDD, however widely-accepted or reasonable, is neither sufficient nor valid as evidence that any particular definition of depression better represents MDD, or captures the biological mechanisms behind MDD.
Our findings indicate the need for ways to assess symptoms for diagnosing MDD with specificity and at scale. Fast and accurate diagnostic methods that use a limited number of questionnaire items are becoming available: for example, computerized adaptive diagnostic screening may be as effective for the diagnosis of MDD as an hour-long face-to-face clinician diagnostic interview 67 . Furthermore, there are ongoing attempts to convert behavioural health tracking data from phones or wearable devices into diagnostic information 68 . If successful, these attempts may lead to a dramatic expansion in our ability to collect data appropriate for psychiatric genetics. The need for the development and implementation of such novel approaches, rather than reliance on minimal phenotyping, is apparent from the genetic analyses we have carried out. We expect that combining genetic and novel phenotyping approaches could be a powerful solution to the problem of acquiring high quality psychiatric phenotypes at scale and a low cost.
Methods
Control for population structure
We performed principal component analysis (PCA) on directly genotyped SNPs from samples in UKBiobank and used PCs as covariates in all our analyses to control for population structure. From the array genotype data, we first removed all samples who did not pass QC, leaving 337,198 White-British, unrelated samples. We then removed SNPs not included in the phasing and imputation and retained those with minor allele frequencies (MAF) >= 0·1%, and P value for violation of Hardy-Weinberg equilibrium > 10 -6 , leaving 593,300 SNPs. We then removed 20,567 SNPs that are in known structural variants (SVs) and the major histocompatibility complex (MHC) 38 as recommended by UKBiobank 69 , leaving 572,733 SNPs that we consistently use for all analyses. Of these, 334,702 are common (MAF > 5%), and from these common SNPs we further filtered based on missingness <0·02 and pairwise LD r 2 < 0·1 with SNPs in a sliding window of 1000 SNPs to obtain 68,619 LD-pruned SNPs for computing PCs using flashPCA 70 . We obtained 20 PCs, their eigenvalues, loadings and variance explained, and consistently use these PCs as covariates for all our genetic analyses. We note that control over population structure over the SVs and MHC is minimal, and we explore the impact of this in Supplemental Methods, Supplemental Table S4-6 and Supplemental Figure S2 .
Imputed genotype filtering
We performed stringent filtering on imputed variants (version 2) used for GWAS in this study, removing variants not among the 33,619,058 variant sites in the Haplotype Reference Consortium 71 (HRC) panel, then removing all insertions and deletions (INDELs) and multi-allelic SNPs. We hard-called genotypes from imputed dosages at 8,968,715 biallelic SNPs with imputation INFO score greater than 0·9, MAF greater than 0·1%, and P value for violation of Hardy-Weinberg equilibrium > 10 -6 , with a genotype probability threshold of 0·9 (anything below would be considered missing). Of these, 5,276,842 SNPs are common (MAF > 5%). We consistently use these SNPs for all analyses in this study.
Genome-wide associations
To obtain and access the difference between odds ratios of associations in different definitions of depression in UKBiobank, as well as smoking (data field 20160) and neuroticism (data field 20127), we perform logistic regression (or linear regression with --standard-beta for neuroticism) on all 5,276,842 common SNPs (MAF > 5% in all 337,198 White-British, unrelated samples) in PLINK (version 1·9) 72 with 20 PCs and genotyping array as covariates. We report all associations with P values smaller than 5 x 10 -8 as genomewide significant. We indicated the SNPs in SVs and the MHC in tables of top hits as well as all manhattan plots as hollow points instead of solid points due to lack of control for population structure in these regions, and do not interpret potential causal effects in these regions ( Supplemental Tables S10-11 
Estimation of SNP-heritability and genetic correlation among definitions of MDD
All estimates of h 2 SNP we refer to in the main text of this paper are computed with the phenotype-correlationgenotype-correlation (PCGC) 73 Supplemental Table S13 .
Estimation of genetic correlation between definitions of MDD and other conditions
We obtained summary statistics for other psychiatric conditions from previous GWAS studies as described in Supplemental Table S1 . We also performed GWAS on smoking and neuroticism in UKBiobank (Supplemental Table S15 Supplemental Figure S10 ) to generate their association summary statistics.
We estimated the genetic correlation between definitions of MDD in UKBiobank with each of these conditions with LDSC 74 , with a LD reference panel generated with EUR individuals from 1000 Genomes 75 , using SNPs with association statistics available in both conditions in each instance. To obtain regional genetic correlation, we partitioned the genome into 1703 independent loci 76 and estimated regional genetic correlation at each locus with rho-HESS 47 , using a LD reference panel generated with EUR individuals from 1000 Genomes 75 . We estimated standard errors for each regional genetic correlation and the cumulative genetic correlations across the genome using a jackknife approach implemented in HESS 37 . To estimate the percentage of loci needed to explain 90% of the total genetic correlation for both LifetimeMDD and GPpsy with all conditions, we ranked all independent loci by their absolute genetic correlation (such that a locus with large negative genetic correlation counts just as much as that with a large positive genetic correlation), and asked genetic correlation contributions from how many loci would sum up to 90% of the total genetic correlation.
Enrichment of SNP-heritability in genes specifically expressed in tissues
We estimate the enrichment of h 2 SNP in genes specifically expressed in 44 tissues in the Genotype-Tissue Expression (GTEx) 48 project using the partitioned h 2 SNP framework in LDSC-SEG 49 , and a LD reference panel generated with EUR individuals from 1000 Genomes 75 . We first obtained tissue specific gene expression annotations in GTEx tissues from LDSC-SEG, then estimated the enrichment of h 2 SNP in annotations that corresponded to each of the tissues together with 52 annotations in the baseline model 77 which we also obtain from LDSC-SEG. We report the P value of the one-sided test of enrichment of h 2 SNP (positive regression coefficient for the tissue-specific annotation conditioning on other baseline annotations) in genes specifically expressed in each tissue against the baseline.
Meta-analysis between PGC29 and LifetimeMDD
We obtained summary statistics of meta-analysis of GWAS on 29 MDD cohorts in the Psychiatric
Genomics Consortium (PGC29) through the MDD Working Group of the Psychiatric Genomics
Consortium (PGC-MDD), reported in Wray et al 2018 5 . Prior to meta-analysis with LifetimeMDD, we removed all INDELs, as well as SNPs with MAF < 5% and imputation INFO score < 0.9, leaving 5,828,030 SNPs. We use this set of summary statistics for estimation of h 2 SNP with LDSC, as well as for enrichment analyses in LDSC-SEG. We then performed a meta-analysis between the filtered summary statistics of PGC29 with those of LifetimeMDD using METAL 78 using the SCHEME STDERR. We removed those SNPs at which no meta-analysis was performed due to their absence in either dataset. The final meta-analysed data contained summary statistics at 4,693,521 SNPs, which we used for estimation of h 2 SNP with LDSC, as well as for enrichment analyses in LDSC-SEG.
Out of sample predictions of MDD
We carried out an out-of-sample prediction using individual level genotype and phenotype data from MDD cohorts 5 among PGC29 in Wray et al 2018 5 . We obtained permissions from PGC-MDD for 20 cohorts with sample sizes (both cases and controls) greater than 500, among which 17 recorded endorsement of DSM-5 criteria A for MDD, using the same criteria we did for DSM-based definition LifetimeMDD (Supplemental Methods, Supplemental Table S20 ). To obtain polygenic risk scores (PRS) for each definintion of depression in UKBiobank without confounding from power differences due to sample sizes, we downsampled all definitions to a constant sample size of 50,000 and case prevalence of 0.15 through randomly sampling 7,500 cases from all cases, and 42,500 controls from all controls in each definition. We then obtained PRS using GWAS on the down-sampled data: for each definition of depression in UKBiobank, we obtained SNPs with P values of associations below 8 thresholds (P < 10 -4 , 0.001, 0.01, 0.05, 0.1, 0.2, 0.5 and 1), and LD clumped them (LD r 2 < 0.1) to obtain independent SNPs. We then used independent SNPs for each threshold and each definition of depression in UKBiobank to construct polygenic risk scores (PRS) and predict MDD status in the 20 PGC cohorts using the Ricopili pipeline 79 . We obtained Nagelkerke's r 2 between the PRS and MDD status, AUC of the prediction, and variance of MDD status explained by the PRS for each cohort. We also obtained the same measures for MDD status pulling data from all cohorts, controlling for cohort differences by including it as a covariate. Supplemental Table S1 ), including schizophrenia 51 (SCZ) and bipolar disorder 52 (BIP) ( Supplemental Table S1 ). b) This figure shows the cumulative fraction of regional genetic correlation "rG" (out of sum of regional genetic correlation across all loci) between definitions of MDD in UKBiobank with SCZ in 1703 indepedent loci in the genome 76 estimated using rho-HESS 47 , plotted against percentage of independent loci. DSM-based LifetimeMDD is shown in purple while help-seeking based GPpsy is shown in red. The steeper the curve, the smaller the number of loci explain the total genetic correlation.
The dotted coloured curves around each solid line represent the standard errors of the estimate computed using a jackknife approach as described in Shi et al 2016 37 . The dotted black line represents 100% of the sum of genetic correlation between each definition of MDD in UKBiobank with SCZ. The cumulative sums of positive regional genetic correlations (right of y axis) go beyond 100% -this is mirrored by the negative regional genetic correlation (left of y axis) that go below 0%. c) We rank all 1703 loci by their magnitude of genetic correlation, and ask what fraction of loci sums up to 90% of total genetic correlation. This figure shows the percentage of loci summing up to 90% of total genetic correlation "rG" between either LifetimeMDD (in purple) or GPpsy (in red) with all psychiatric conditions tested, with standard errors estimated using the same jackknife approach. The higher the percentage, the higher the number of genetic loci contributing to 90% of total genetic correlation. UKBiobank with MDD status indicated in all 20 PGC cohorts, while controlling for cohort specific effects.
PRS were calculated using effect sizes at independent (LD r 2 < 0.1) SNPs passing P value thresholds 10 -4 , 0.001, 0.01, 0.05, 0.01, 0.2, 0.5 and 1 respectively, in GWAS performed on down-sampled data ( 
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